PTC Therapeutics, Inc. (PTCT)
NEUTRALFundamental
58
Precio
$72.49
Capitalización Bursátil
$5.77B
Parte 1 · Cuánto vale la empresa
Resumen
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.01B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-38M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$702M
Patrimonio Neto Total
$-205M
Pasivo Total
$3.10B
Ratio de Liquidez
3.39
Cobertura de Intereses
-
Deuda/EBITDA
0.77
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$150.93
Precio Actual
$72.49
Margen de Seguridad
+52.0%
Rango de Valor Justo
$98.10 - $203.75
Métodos de Estimación
Métricas de Valoración
Ratio P/E
8.89
ROE
-332.5%
Ratio P/B
-
P/FCF
8.22
Margen Bruto
-
ROIC
4.0%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
4.0%
WACC
7.2%
ROIC − WACC
-3.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (10)
- EPS shows upward trend
- Price CAGR 20.40%
- P/FCF 8.22
- Operating Margin 12.5%
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Revenue Growth 5Y 135.4%
- Analyst Consensus 81% Buy
- Piotroski F-Score 6/9
Fallido (9)
- EPS CAGR 3.91%
- ROIC 4.0%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -351.9%
- Earnings Surprise avg -1034.0%
- Share Dilution 14.2%
- Net Margin Trend -3.8% vs 35.6%
No disponible (9)
- Gross Margin NaN%
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 53 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 79 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 40 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 58 |
| Mr. Eric Pauwels | Chief Business Officer | 63 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 57 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 46 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | - |
| Ms. Ellen Cavaleri | Head of Investor Relations | - |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 64 |
Riesgo de Auditoría
3
Riesgo del Consejo
3
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for PTCT, sourced from Markets Gazette.
- 3/3/2026POSITIVEInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Investor confidence in PTC Therapeutics (PTCT) appears to be on the rise, following a recent SEC filing that disclosed a significant purchase of 41,000 shares by an investment manager. This strategic move suggests a positive outlook on the future of the company, which specializes in developing therapies for rare diseases. The increased stake by an institutional player can be interpreted as a bullish signal, indicating that the market might be underestimating the potential of PTC Therapeutics' portfolio of commercial products and investigational candidates. Investors should closely monitor the stock's performance, as such an endorsement often precedes positive price movements, reflecting stronger conviction in the company's business model and long-term growth prospects within the biopharmaceutical sector.
via Markets Gazette